SRPT,CRWG,UNRH,MITK,ZIOP,UNRH,RENN,MAXD,SFIN,ZAGG -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Simply Wall St.7 hours ago

    Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

    Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT): Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. Read More...

  • Moody'syesterday

    ASG Technologies Group, Inc. -- Moody's says ASG Technologies' ratings unaffected by the revised offer to acquire Mitek

    Moody's Investors Service (Moody's) said that ASG Technologies Group, Inc.'s B2 Corporate Family Rating and stable ratings outlook are not affected at this time by ASG's increased offer to acquire Mitek Systems, Inc. On 10 December 2018, ASG Technologies Group, Inc. and the affiliates of Elliott Associates, L.P., ASG's financial sponsors, made public their increased offer to acquire Mitek Systems, Inc. for $11.50 per share in cash, up from the $10 per share offer that was made public on 31 October 2018.

  • Reutersyesterday

    Mitek rejects ASG's latest offer, says undervalues company

    In a public letter released on Monday, hedge fund Elliott Management Corp's ASG Technologies raised its offer to buy Mitek to $11.50 per share from $10 previously on Oct. 31. Following ASG's latest offer, Mitek said it offered ASG the opportunity to access preliminary diligence on a confidential, non-exclusive basis to provide ASG an opportunity to increase its offer price. "We requested that ASG and Elliott agree to a confidentiality agreement, including a customary standstill, to prevent the misuse of the company's confidential and proprietary information," Mitek said.

  • Reutersyesterday

    Mitek rejects ASG's latest offer, says undervalues company

    Mitek Systems Inc on Tuesday rejected ASG Technologies Group Inc's latest buyout offer, saying it undervalued the financial technology provider. In a public letter released on Monday, hedge fund Elliott Management Corp's ASG Technologies raised its offer to buy Mitek to $11.50 per share from $10 previously on Oct. 31. Following ASG's latest offer, Mitek said it offered ASG the opportunity to access preliminary diligence on a confidential, non-exclusive basis to provide ASG an opportunity to increase its offer price.

  • GuruFocus.com2 days ago

    US Stocks Rebound Monday

    Elliott Management's ASG Technologies Group increases offer to buy Mitek Systems

  • Reuters2 days ago

    ASG raises offer to buy Mitek to $11.50 per share

    Hedge fund Elliott Management Corp's ASG Technologies Group Inc raised its offer to buy Mitek Systems Inc to $11.50 per share from $10, in its latest attempt to buy the provider of financial technology to banks. ASG said it made the offer public because Mitek refused to engage with the hedge fund on "reasonable terms." Mitek could not immediately be reached for comment. Mitek's shares were up 10 percent at $9.96.

  • Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?

    Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of ZIOP earnings conference call or presentation 12-Nov-18 1:00pm GMT

    Q3 2018 ZIOPHARM Oncology Inc Earnings Call

  • With A -16% Earnings Drop, Did Renren Inc (NYSE:RENN) Really Underperform?
    Simply Wall St.8 days ago

    With A -16% Earnings Drop, Did Renren Inc (NYSE:RENN) Really Underperform?

    Examining Renren Inc’s (NYSE:RENN) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, which Read More...

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Sarepta Therapeutics Inc NASDAQ/NGS:SRPT

  • How BioMarin Pharmaceutical’s Financials Look in November
    Market Realist13 days ago

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.

  • Wall Street Analysts Are Mostly Positive on BioMarin
    Market Realist13 days ago

    Wall Street Analysts Are Mostly Positive on BioMarin

    BioMarin Pharmaceutical’s net income and EPS for the first nine months of this year amounted to -$73.6 million and -$0.42, respectively, compared to -$65.7 million and -$0.38 in the same period the prior year.

  • Are Options Traders Betting on a Big Move in ZIOPHARM Oncology (ZIOP) Stock?
    Zacks13 days ago

    Are Options Traders Betting on a Big Move in ZIOPHARM Oncology (ZIOP) Stock?

    Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.

  • Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
    Zacks13 days ago

    Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines

    Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines

  • 5 Stocks With Recent Price Strength to Strengthen Portfolio
    Zacks14 days ago

    5 Stocks With Recent Price Strength to Strengthen Portfolio

    Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Sarepta Therapeutics Inc NASDAQ/NGS:SRPT

  • Sarepta Stock More Than Doubles This Year So Far: Here's Why
    Zacks19 days ago

    Sarepta Stock More Than Doubles This Year So Far: Here's Why

    Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.

  • 5 Affordable Breakout Stocks Providing Attractive Returns
    Zacks19 days ago

    5 Affordable Breakout Stocks Providing Attractive Returns

    This approach involves identifying stocks whose prices are varying within a narrow band.

  • Reuters22 days ago

    Hedge fund Elliott raises pressure on Mitek after takeover bid rejected

    Hedge fund Elliott Management on Tuesday asked Mitek Systems Inc to scrap a so-called "poison pill" to let it buy more stock and said it may press for board changes after the software company took steps to protect itself from the activist investor. Elliott, which invests more than $34 billion, wrote to Mitek's board and asked for "relief from the poison pill recently enacted" in order to buy as much as 14.9 percent of the company's stock. Elliott has not disclosed the size of its stake, which includes common stock and swaps, but has said it is one of the company's biggest shareholders.

  • Reuters22 days ago

    Hedge fund Elliott raises pressure on Mitek after takeover bid rejected

    Hedge fund Elliott Management on Tuesday asked Mitek Systems Inc to scrap a so-called poison pill to let it buy more stock and said it may press for board changes after the software company took steps to protect itself from the activist investor. Elliott is increasing the pressure on San Diego-based Mitek at a time that software company ASG Technologies, which the hedge fund owns, has been pushing to buy Mitek for $10 a share. Elliott wrote that ASG President and Chief Executive Charles Sansbury first approached Mitek about a possible takeover in August, roughly one week before the company announced that long-serving CEO James DeBello and chief financial officer Jeff Davison would be leaving.

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of MITK earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q4 2018 Mitek Systems Inc Earnings Call

  • Paul Singer Adds 6 Stocks to Portfolio
    GuruFocus.com26 days ago

    Paul Singer Adds 6 Stocks to Portfolio

    Elliott Management leader Paul Singer (Trades, Portfolio) disclosed that he established six new positions when he released his third-quarter portfolio earlier this week. Warning! GuruFocus has detected 5 Warning Signs with FE. As a well-known activist investor, the guru's New York-based firm takes large stakes in underperforming companies and then encourages management to implement changes that will improve performance and profitability.

  • Benzinga26 days ago

    The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 15) Vapotherm, Inc. (NYSE: VAPO ) Down In The Dumps (Biotech ...

  • Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
    Zacks28 days ago

    Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges

    With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.

  • The forgotten 'Facebook of China' is sold for $20M
    TechCrunch29 days ago

    The forgotten 'Facebook of China' is sold for $20M

    Renren, which was once heralded as the 'Facebook of China' and later became China's answer to MySpace after falling out of fashion among its core young users, is selling its social networking business. Renren's parent company Beijing Qianxiang Wangjing has agreed to sell all tangible and intangible assets of renren.com to Beijing Infinities Interactive Media, according to a statement. As part of the deal, Qianxiang will receive $40 million worth of shares in Beijing Infinities, a $700 million firm that owns one of China's major IT news sites DoNews.